Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6-Reference-Cited by-同舟云学术

Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6

Published:2023-09 Issue: Volume:30 Page:48-64
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Mellen Russell W.,Calabro Kaitlyn R.,McCullough K. Tyler,Crosson Sean M.,Cova Alejandro de la,Fajardo Diego,Xu Emily,Boye Sanford L.,Boye Shannon E.^ORCID

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference42 articles.

1. Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy;Gill;Br. J. Ophthalmol.,2019

2. Phenotype of autosomal dominant cone-rod dystrophy due to the R838C mutation of the GUCY2D gene encoding retinal guanylate cyclase-1;Smith;Eye,2007

3. Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy;Kelsell;Hum. Mol. Genet.,1998

4. Clustering and frequency of mutations in the retinal guanylate cyclase (GUCY2D) gene in patients with dominant cone-rod dystrophies;Payne;J. Med. Genet.,2001

5. Functional characterization of missense mutations at codon 838 in retinal guanylate cyclase correlates with disease severity in patients with autosomal dominant cone-rod dystrophy;Wilkie;Hum. Mol. Genet.,2000

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optogenetics and Targeted Gene Therapy for Retinal Diseases: Unravelling the Fundamentals, Applications, and Future Perspectives;Journal of Clinical Medicine;2024-07-19

2. Exploring the Potential and Challenges of CRISPR Delivery and Therapeutics for Genetic Disease Treatment;Advanced Functional Materials;2024-05-27